Pleiotropic effects of statins: The role of eicosanoid production

Yochai Birnbaum, Yumei Ye

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

The 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) have potent anti-inflammatory, vasodilatory and anti-platelet effects that are independent of the lipid-lowering effects. These non-lipid-lowering or pleiotropic effects are dependent on HMG-CoA reductase inhibition in tissues other than the liver. In animal models, high-dose statins upregulate cytosolic phospholipase A 2 and cyclooxygenase-2, leading to increased production of prostacyclin and 15-deoxy-PGJ 2. In addition, statins activate protein kinase A, which phosphorylates 5-lipoxygenase, resulting in decreased production of the pro-inflammatory leukotrienes and increased production of 15-epi-lipoxin A4, an eicosanoid with potent anti-inflammatory and inflammation-resolution properties. It is unclear, however, whether these effects occur in the clinical setting and whether these effects (partially) explain the anti-inflammatory effects of statins in patients.

Original languageEnglish (US)
Pages (from-to)135-139
Number of pages5
JournalCurrent Atherosclerosis Reports
Volume14
Issue number2
DOIs
StatePublished - Apr 2012

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Eicosanoids
Anti-Inflammatory Agents
Oxidoreductases
Arachidonate 5-Lipoxygenase
Leukotrienes
Phospholipases A
Epoprostenol
Cyclooxygenase 2
Cyclic AMP-Dependent Protein Kinases
Up-Regulation
Blood Platelets
Animal Models
Inflammation
Lipids
Liver
3-hydroxy-3-methylglutaryl-coenzyme A

Keywords

  • 5-lipooxygenase
  • Arachidonic acid
  • Aspirin
  • Cyclooxygenase-2
  • Eicosanoids
  • Inflammation
  • LDL cholesterol
  • Pleiotropic effects
  • Prostacyclin
  • Protein kinase A (PKA)
  • Statins

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Pleiotropic effects of statins : The role of eicosanoid production. / Birnbaum, Yochai; Ye, Yumei.

In: Current Atherosclerosis Reports, Vol. 14, No. 2, 04.2012, p. 135-139.

Research output: Contribution to journalArticle

@article{35d4b2e9b12941708695629ddcc1cf37,
title = "Pleiotropic effects of statins: The role of eicosanoid production",
abstract = "The 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) have potent anti-inflammatory, vasodilatory and anti-platelet effects that are independent of the lipid-lowering effects. These non-lipid-lowering or pleiotropic effects are dependent on HMG-CoA reductase inhibition in tissues other than the liver. In animal models, high-dose statins upregulate cytosolic phospholipase A 2 and cyclooxygenase-2, leading to increased production of prostacyclin and 15-deoxy-PGJ 2. In addition, statins activate protein kinase A, which phosphorylates 5-lipoxygenase, resulting in decreased production of the pro-inflammatory leukotrienes and increased production of 15-epi-lipoxin A4, an eicosanoid with potent anti-inflammatory and inflammation-resolution properties. It is unclear, however, whether these effects occur in the clinical setting and whether these effects (partially) explain the anti-inflammatory effects of statins in patients.",
keywords = "5-lipooxygenase, Arachidonic acid, Aspirin, Cyclooxygenase-2, Eicosanoids, Inflammation, LDL cholesterol, Pleiotropic effects, Prostacyclin, Protein kinase A (PKA), Statins",
author = "Yochai Birnbaum and Yumei Ye",
year = "2012",
month = "4",
doi = "10.1007/s11883-012-0232-5",
language = "English (US)",
volume = "14",
pages = "135--139",
journal = "Current Atherosclerosis Reports",
issn = "1523-3804",
publisher = "Current Medicine Group",
number = "2",

}

TY - JOUR

T1 - Pleiotropic effects of statins

T2 - The role of eicosanoid production

AU - Birnbaum, Yochai

AU - Ye, Yumei

PY - 2012/4

Y1 - 2012/4

N2 - The 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) have potent anti-inflammatory, vasodilatory and anti-platelet effects that are independent of the lipid-lowering effects. These non-lipid-lowering or pleiotropic effects are dependent on HMG-CoA reductase inhibition in tissues other than the liver. In animal models, high-dose statins upregulate cytosolic phospholipase A 2 and cyclooxygenase-2, leading to increased production of prostacyclin and 15-deoxy-PGJ 2. In addition, statins activate protein kinase A, which phosphorylates 5-lipoxygenase, resulting in decreased production of the pro-inflammatory leukotrienes and increased production of 15-epi-lipoxin A4, an eicosanoid with potent anti-inflammatory and inflammation-resolution properties. It is unclear, however, whether these effects occur in the clinical setting and whether these effects (partially) explain the anti-inflammatory effects of statins in patients.

AB - The 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) have potent anti-inflammatory, vasodilatory and anti-platelet effects that are independent of the lipid-lowering effects. These non-lipid-lowering or pleiotropic effects are dependent on HMG-CoA reductase inhibition in tissues other than the liver. In animal models, high-dose statins upregulate cytosolic phospholipase A 2 and cyclooxygenase-2, leading to increased production of prostacyclin and 15-deoxy-PGJ 2. In addition, statins activate protein kinase A, which phosphorylates 5-lipoxygenase, resulting in decreased production of the pro-inflammatory leukotrienes and increased production of 15-epi-lipoxin A4, an eicosanoid with potent anti-inflammatory and inflammation-resolution properties. It is unclear, however, whether these effects occur in the clinical setting and whether these effects (partially) explain the anti-inflammatory effects of statins in patients.

KW - 5-lipooxygenase

KW - Arachidonic acid

KW - Aspirin

KW - Cyclooxygenase-2

KW - Eicosanoids

KW - Inflammation

KW - LDL cholesterol

KW - Pleiotropic effects

KW - Prostacyclin

KW - Protein kinase A (PKA)

KW - Statins

UR - http://www.scopus.com/inward/record.url?scp=84861230309&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861230309&partnerID=8YFLogxK

U2 - 10.1007/s11883-012-0232-5

DO - 10.1007/s11883-012-0232-5

M3 - Article

C2 - 22286195

AN - SCOPUS:84861230309

VL - 14

SP - 135

EP - 139

JO - Current Atherosclerosis Reports

JF - Current Atherosclerosis Reports

SN - 1523-3804

IS - 2

ER -